Over 34 million people have diabetes, 88 million people have prediabetes, and obesity rates are rising. “Diabesity” is projected to dramatically increase in the next few years. This course reviews the latest American Diabetes Association (ADA) pharmacotherapy standards of care and recommended treatment so you can provide person-centered care, education, and adherence assessment.

Upon successful completion of this application-based CPE course, pharmacists should be able to:
1. Summarize recent changes to the American Diabetes Association Management of Hyperglycemia in Type 2 Diabetes.
2. Discuss the rationale regarding therapeutic decision making when selecting medication therapy for people with type 2 diabetes.
3. Evaluate contraindications and adverse effect considerations when recommending therapies for people with type 2 diabetes.
4. Formulate patient-centered treatment plans for people with diabetes to reduce cardio-metabolic and renal risk.

Susan Cornell, PharmD, CDCES, FAPhA, FADCES
Professor
Midwestern University College of Pharmacy Downers Grove

Susan Cornell is an advisory board member for Bayer and Sanofi and an advisory board member and speaker’s bureau member for Novo Nordisk. All relevant financial relationships have been mitigated.

Course fee includes course, course materials, and CPE credit submission to CPE Monitor.
Course is non-refundable.
Initial Release Date: February 1, 2022
Planned Expiration Date: February 1, 2025

Copyright 2022, CEimpact. All Rights Reserved. Any reproduction of this course without express permission is strictly forbidden.  

RV2-10.23/EXP